European Journal of Molecular & Clinical Medicine

ISSN 2515-8260 Volume 07, Issue 07, 2020

# A REVIEW STUDY ON THE RELATIONSHIP AMONG COVID-19 AND CARDIOVASCULAR DISEASE

**Dr. Sankaralingam P Professor & HOD[1],**

**Dr. Vijaya Suriya R Senior Resident[2]**

*Meenakshi Academy of Higher Education and Research*

*sankaralingamp@mmchri.ac.in*

***Abstract***

***In the scenery for Coronavirus Disease 2019 (COVID-19), the early data has indicated a decline in presentation and an improvement in pre-hospital latency for acute patients with stroke or AMI,3,4 the condition in Michigan, but it is not clear how acute stroke and AMI (COVID-18) should be administered and how these are treated. In reported cases and deaths, COVID-19 has had a disproportionate effect on Black Americans. Blacks make up about 14 percent of the population in Michigan but 19 percent of cases of COVID–19 and 36% of the deaths by October 22, 2020.5 The rise in the incidence of pre-hospital delay among Black Americans which further worsen established racial disorders6 compared with their white counterparts. We wanted to use a quick appraisal methodology in order to advise existing and prospective public health camps, both locally and globally, because of the pressing repercussions for clinical and public health.***

***Keywords: COVID-19, Pandemic, Cardiovascular Disease***

## BACKGROUND

Covid-19, the extreme SRAS-CoV2 coronavirus acute respiratory syndrome, has caused more than 39 million infected and 1 million worldwide deaths since the first cases recorded in the Chinese City of Wuhan in December 2019. The condition may progress rapidly from fever, toughness, shortness of breath and scent and taste changes to acute respiratory arrest, septic shock. The lipidom of corrupted calls is well known to be restored by SARS-CoV and

ISSN 2515-8260 Volume 07, Issue 07, 2020

MERS-CoV. Therefore, this letter is aimed at introducing and debating the details available in COVID-19 patients on improvements in lipid metabolites found[1–3].

Various research efforts have in reality begun to report the metabolic feature of COVID-19 alterations. The hallmark characteristics are I a decrease in LDL and HDL-c levels in lipoproteins, later relative to the severity of the symptoms, and ii) a mild rise in T helpers' cell population (CD3+T, CD4+ T) or CD8+T lymphopenia (suggesting potential invasion of certain cells or exhaustion of the immune system) and iii) hyper-inflammation. Hyper-inflammatory disorders are characterised by The overall count of White Blood Cells was also slightly higher in those who were seriously affected, although the involvement of monocyte-recruiting chemokines in bronchoalveolar fluid was reported as a macrophage activation syndrome in those with serious respiratory failure[4–8].

**COVID AND RNA**

CoronaVIrus Infection with CoronaVirus 2 Severe Acute Respiratory Syndrome 19 (COVID-19) is caused by the infection (SARS-CoV-2). Although COVID-19 is primarily respiratory clinical, many patients may have acute myocardial injuries and chronic cardiovascular injury. In order to identify optimal health treatment methods, including overt and indirect disruption to the heart and the vascular system caused by SARS-CoV-2[9–12]. A closely regulated gene expression of the homeostasis of the cardiovascular system includes various forms of RNA molecules, such as RNA encoding proteins (messgers RNAs) and those without protein encoding potentials (non-coding RNAs). In recent years, non-coding RNAs dysregulation has appeared to be a key component of nearly any cardiovascular disorder in pathophysiology. Here we will address the possible role and usage as biomarkers for clinical use of non-coding RNAs in COVID-19 disease mechanisms[13–17].

CoronaVirus 2 (SARS-CoV-2), a novel man isolated from 7 January 2020, was identified as a source of unexplained cases of acute respiratory disruptions (ARDS) observed in the city of Wuhan, Hubei, China and was then identified as Coronavirus 2019 (COVID-19). As a result of the accelerated global dissemination of the COVID-19, more than 43 million cases have been confirmed and over 1 million deaths have been observed globally by the Director General of the World Health Organisation (WHO) as a pandemic by October 27 2020[18,19].

COVID-19 is primarily medicinal in its respiratory manifestations. Many patients, however, still show serious cardiovascular involvement. The overt and indirect damage to the SARS-

ISSN 2515-8260 Volume 07, Issue 07, 2020

CoV-2 cardiovascular system, and the underlying pathogenetic pathways, is therefore of utmost importance[20,21].

## COVID AND CARDIOVASCULAR DISEASE

In this section we will discuss the role of transcriptomics in our interpretation of the processes of human cardiovascular coronavirus disease and in defining possible clinical application biomarkers. In specific, we are focusing on non-coding RNAs (ncRNAs), an evolving class of regulatory RNAs. Because of their fundamental role in the regulation of gene expression, ncRNAs are promising candidate countries to consider the cardiovascular system implications of SARS-CoV-2 infection. In addition, as a result of improvements in the attitudes of patients and the healthcare behaviour and health sector reorganisation, the pandemic has had secondary impacts beyond the immediate effects of COVID-19 on people of all countries. Therefore it is important to consider the indirect impact of the pandemic on non-communicable diseases both for disease risk and for availability of health care to prepare and adapt the responses to current and possible risks to public health[22–26]. The main causes of death and morbidity in the UK and internationally are cardiovascular diseases (CVDs). In addition, the preceding CVD is an important risk factor for COVID-19 complications and mortality. Government advice has instructed people on physical separation of CVD to pay careful attention. Concerns over services after the pandemic, from prevention to recovery, have been addressed and statistics from several countries which have indicated decreased service operation have been promoted. Official national figures suggest a host of non-COVID-9 deaths and CVDs and a drop in the attendance of cardiac emergency departments (ED) in the UK have also been noted for drops in activities across CVDs[27–32].

## DISCUSSION

In addition to regular primary and secondary care reports, several national CVD disease-specific audits are available. These outlets, however, frequently fall behind in real-time some weeks or months, cannot cover the United Kingdom's devolved nations and are not currently available for review. Changes in service delivery happening through the pandemic need to be determined for audit, quality management, surveillance and to advise policy responses. In the aftermath of the pandemic, it has been seen that open, public-oriented knowledge has a real benefit both for patients, the public, academics, physicians and politicians[33–36].

ISSN 2515-8260 Volume 07, Issue 07, 2020

Coronavirus-2 Extreme ART (SARS-CoV-2) is a member of the Wuhan City, Chinese RNA family beta-human coronavirus. On 12 December 2019 the case of COVID-19 first was admitted to the centre and the patients' primary process was first identified on 6 January 2020. In mid-January 2020 also the transmission of people to people was seen. Since 4 February 2020, 3rd and 4th transmitting processes have had to be taken into consideration. In Wuhan, China revealed the scene of atypical SARS-CoV-2 pneumonia. The country has been transmitted uniformly by pollution since December 2019. Effective on 2 March 2020, more than 89 000 cases of COVID-19 have been reported from all regions of China, and 66 countries worldwide. The European Center for Ailment prevention and surveillance[37–41]. This beta coronaviruses are seven species that have caused human infections. There were four forms of coronavirus that displayed prevalent symptoms, including small bit phlegm, but symptoms were potentially lethal for SARS (Severe ARS), MERS (Middle East Respiratory Syndrome) and COVID-19. Cardiometabolic demand associated with simple emissions and hypoxia symptoms can reduce myocardial oxygeal requests due to severe respiratory distress — gracefully connected which may lead to serious myocardial infarction. An increased shear issue caused by fundamental discomfort will lead to intensive myocardial-localized necrosis just as extended coronary blood stream. The prothrombotic environment created by simple agitation further raises the risk of coronary and plaque breakdown. The electrolyte can be imbalanced and cause arythmia precipitation as this can be seen with patients with cardiac dysfunction due to total disease. The activity of COVID-19 mechanism renin-angiotensin aldosterone may cause hypokalemia in patients with COVID-19, which may result in enhanced tachyarrhythmia being at risk of quick fatality and mortality[42,43].

**REFERENCES:**

1. Robles MC, Corches CL, Bradford M, et al. Understanding and Informing Community Emergency Cardiovascular Disease Preparedness during the COVID-19 Pandemic: Stroke Ready. *J Stroke Cerebrovasc Dis*. 2021;30(2). doi:10.1016/j.jstrokecerebrovasdis.2020.105479

2. Andreini D, Conte E, Mushtaq S, et al. Extent of lung involvement over severity of cardiac disease for the prediction of adverse outcome in COVID-19 patients with cardiovascular disease. *Int J Cardiol*. 2021;323:292-294. doi:10.1016/j.ijcard.2020.10.006

3. Agarwal MA, Ziaeian B, Lavie CJ, Fonarow GC. Cardiovascular Disease in Hospitalized Patients With a Diagnosis of Coronavirus From the Pre–COVID-19 Era in United States: National Analysis From 2016-2017. *Mayo Clin Proc*. 2020;95(12):2674-2683. doi:10.1016/j.mayocp.2020.09.022

4. Greco S, Madè A, Gaetano C, Devaux Y, Emanueli C, Martelli F. Noncoding RNAs implication in cardiovascular diseases in the COVID-19 era. *J Transl Med*. 2020;18(1). doi:10.1186/s12967-020-02582-8

5. Ball S, Banerjee A, Berry C, et al. Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK. *Heart*. 2020;106(24):1890-1897. doi:10.1136/heartjnl-2020-317870

6. Ribera A, Mauri Ferré J, Romaguera R. Competing risk largely explains the drop in admissions for acute cardiovascular disease during the COVID-19 pandemic. Response [El riesgo competitivo puede explicar en gran medida la disminución de los ingresos por enfermedad cardiovascular aguda durante la pandemia de COVID-19. Respuesta]. *Rev Esp Cardiol*. 2020;73(12):1085. doi:10.1016/j.recesp.2020.08.015

7. Dan S, Pant M, Upadhyay SK. The Case Fatality Rate in COVID-19 Patients With Cardiovascular Disease: Global Health Challenge and Paradigm in the Current Pandemic. *Curr Pharmacol Reports*. 2020;6(6):315-324. doi:10.1007/s40495-020-00239-0

8. Rodríguez-Padial L, Arias MÁ. Competing risk largely explains the drop in admissions for acute cardiovascular disease during the COVID-19 pandemic [El riesgo competitivo puede explicar en gran medida la disminución de los ingresos por enfermedad cardiovascular aguda durante la pandemia de COVID-19]. *Rev Esp Cardiol*. 2020;73(12):1084-1085. doi:10.1016/j.recesp.2020.07.022

9. Momtazmanesh S, Shobeiri P, Hanaei S, Mahmoud-Elsayed H, Dalvi B, Malakan Rad E. Cardiovascular disease in COVID-19: a systematic review and meta-analysis of 10,898 patients and proposal of a triage risk stratification tool. *Egypt Hear J*. 2020;72(1). doi:10.1186/s43044-020-00075-z

10. Chakafana G, Mutithu D, Hoevelmann J, Ntusi N, Sliwa K. Interplay of COVID-19 and cardiovascular diseases in Africa: an observational snapshot. *Clin Res Cardiol*. 2020;109(12):1460-1468. doi:10.1007/s00392-020-01720-y

11. Gerstein NS, Venkataramani R, Goumas AM, Chapman NN, Deriy L. COVID-19-Related Cardiovascular Disease and Practical Considerations for Perioperative Clinicians. *Semin Cardiothorac Vasc Anesth*. 2020;24(4):293-303. doi:10.1177/1089253220943019

12. Yan X, Jing L, Deng Y. COVID-19 with Cardiovascular Disease: Can It Help Predict Prognosis? *Heart Surg Forum*. 2020;23(6):E895-E896. doi:10.1532/hsf.3301

13. Xu H, Ai L, Qiu C, et al. COVID-19: a risk factor for fatal outcomes in patients with comorbid cardiovascular disease. *Aging (Albany NY)*. 2020;12(19):18866-18877. doi:10.18632/aging.103944

14. Maines M, Zorzi A, Benetollo PP, et al. Short-term outcome associated with remote evaluation (telecardiology) of patients with cardiovascular diseases during the COVID-19 pandemic. *IJC Hear Vasc*. 2020;30. doi:10.1016/j.ijcha.2020.100625

15. Antza C, Stabouli S. Reduction in environmental noise during COVID-19 pandemic and cardiovascular disease: A mystery for further investigation. *J Clin Hypertens*. 2020;22(10):1947-1948. doi:10.1111/jch.14018

16. Sharma S. COVID-19: A Concern for Cardiovascular Disease Patients. *Cardiovasc Toxicol*. 2020;20(5):443-447. doi:10.1007/s12012-020-09596-0

17. Fisher M. Cardiovascular disease and cardiovascular outcomes in COVID-19. *Pract Diabetes*. 2020;37(5):191-193a. doi:10.1002/pdi.2294

18. Sama IE, Voors AA, Van Veldhuisen DJ. New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease. *Eur Heart J*. 2020;41(41):4047-4049. doi:10.1093/eurheartj/ehaa761

19. Guijarro C. COVID-19 and cardiovascular disease [COVID-19 y enfermedad cardiovascular]. *Clin e Investig en Arterioscler*. 2020;32(6):263-266. doi:10.1016/j.arteri.2020.10.005

20. Kawahara LT, da Silva Costa IBS, Barros CCS, et al. Cancer and cardiovascular diseases during the COVID-19 pandemic [Câncer e Doenças Cardiovasculares na Pandemia de COVID-19]. *Arq Bras Cardiol*. 2020;115(3):547-557. doi:10.36660/abc.20200405

21. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. *Nat Rev Cardiol*. 2020;17(9):543-558. doi:10.1038/s41569-020-0413-9

22. Prabhakaran D, Perel P, Roy A, et al. Erratum: Management of cardiovascular disease patients with confirmed or suspected covid-19 in limited resource settings (Global Heart (2020) 15:1 (44) DOI: 10.5334/gh.823). *Glob Heart*. 2020;15(1). doi:10.5334/GH.885

23. Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. *PLoS One*. 2020;15(8 August). doi:10.1371/journal.pone.0238215

24. Nicholls M. COVID-19 and cardiovascular disease: In a special report, Mark Nicholls speaks to leading cardiologists from four continents to assess their view of the COVID-19 crisis and its potential impact on the battle against cardiovascular disease. *Eur Heart J*. 2020;41(29):2727-2729. doi:10.1093/eurheartj/ehaa567

25. Murphy AC, Koshy AN, Yudi MB. Collateral damage of a global pandemic: implications of COVID-19 for Australians with cardiovascular disease. *Intern Med J*. 2020;50(8):1020-1021. doi:10.1111/imj.14939

26. Morawietz H, Julius U, Bornstein SR. Cardiovascular diseases, lipid-lowering therapies and european registries in the covid-19 pandemic. *Cardiovasc Res*. 2020;116(10):E122-E125. doi:10.1093/cvr/cvaa176

27. Ganatra S, Dani SS, Shah S, et al. Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic. *Trends Cardiovasc Med*. 2020;30(6):315-325. doi:10.1016/j.tcm.2020.05.004

28. Li X, Guan B, Su T, et al. Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: A systematic review and meta-analysis. *Heart*. 2020;106(15):1142-1147. doi:10.1136/heartjnl-2020-317062

29. Zhang J, Lu S, Wang X, et al. Do underlying cardiovascular diseases have any impact on hospitalised patients with COVID-19? *Heart*. 2020;106(15):1148-1153. doi:10.1136/heartjnl-2020-316909

30. Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19–systematic review, meta-analysis, and meta-regression. *J Stroke Cerebrovasc Dis*. 2020;29(8). doi:10.1016/j.jstrokecerebrovasdis.2020.104949

31. Bashir M, Moughal S. Cardiovascular disease and surgery amid COVID-19 pandemic. *J Vasc Surg*. 2020;72(2):405-407. doi:10.1016/j.jvs.2020.04.479

32. Aggarwal G, Cheruiyot I, Aggarwal S, et al. Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis. *Curr Probl Cardiol*. 2020;45(8). doi:10.1016/j.cpcardiol.2020.100617

33. Rastad H, Karim H, Ejtahed H-S, et al. Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease. *Diabetol Metab Syndr*. 2020;12(1). doi:10.1186/s13098-020-00565-9

34. Botly LCP, Martin-Rhee M, Kasiban A, et al. COVID-19 Pandemic: Global Impact and Potential Implications for Cardiovascular Disease in Canada. *CJC Open*. 2020;2(4):265-272. doi:10.1016/j.cjco.2020.06.003

35. Dhakal BP, Sweitzer NK, Indik JH, Acharya D, William P. SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. *Hear Lung Circ*. 2020;29(7):973-987. doi:10.1016/j.hlc.2020.05.101

36. Sciatti E, Ceconi C. Les liaisons dangereuses and the danger of deductions: The interplay between cardiovascular disease and COVID-19. *Eur J Prev Cardiol*. 2020;27(10):1015-1016. doi:10.1177/2047487320925622

37. Wang BX. Susceptibility and prognosis of COVID-19 patients with cardiovascular disease. *Open Hear*. 2020;7(1). doi:10.1136/openhrt-2020-001310

38. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Retraction: Cardiovascular disease, drug therapy, and mortality in Covid-19. *N Engl J Med*. 2020;382(26):2582. doi:10.1056/NEJMc2021225

39. Li M, Dong Y, Wang H, et al. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. *Nutr Metab Cardiovasc Dis*. 2020;30(7):1061-1067. doi:10.1016/j.numecd.2020.04.013

40. Li G, Hu R, Gu X. A close-up on COVID-19 and cardiovascular diseases. *Nutr Metab*

*Cardiovasc Dis*. 2020;30(7):1057-1060. doi:10.1016/j.numecd.2020.04.001

41. Rubin EJ. Erratum: Expression of Concern: Mehra MR et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621. *N Engl J Med*. 2020;382(25):2464. doi:10.1056/NEJMe2020822

42. Barach P, Lipshultz SE. Rethinking COVID-19 in children: Lessons learned from pediatric viral and inflammatory cardiovascular diseases. *Prog Pediatr Cardiol*. 2020;57. doi:10.1016/j.ppedcard.2020.101233

43. Jennings GLR. Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease. *Med J Aust*. 2020;212(11):502-503.e1. doi:10.5694/mja2.50622